Seagen (SGEN): Carillon Eagle Mid Cap Growth Fund’s Top Contributor

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here. The second quarter witnessed a poor overall performance of mid-cap stocks. The Russell Midcap Growth Index was down 21.07% and fell more compared to its counterpart Russell Midcap Value Index (down 14.68%). In the quarter, all sector returns were negative for the Russell Midcap Growth Index due to market volatility. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.

Carillon Tower Advisers discussed stocks like Seagen Inc. (NASDAQ:SGEN) in its second quarter 2022 investor letter. Headquartered in Bothell, Washington, Seagen Inc. (NASDAQ:SGEN) is a biotechnology company. On September 2, 2022, Seagen Inc. (NASDAQ:SGEN) stock closed at $152.34 per share. One-month return of Seagen Inc. (NASDAQ:SGEN) was -13.35% and its shares gained 0.08% of their value over the last 52 weeks. Seagen Inc. (NASDAQ:SGEN) has a market capitalization of $28.097 billion.

Here is what Carillon Tower Advisers specifically said about Seagen Inc. (NASDAQ:SGEN):

Seagen Inc. (NASDAQ:SGEN) is a biotechnology company that develops monoclonal antibody-based therapies to treat cancer. The company’s stock jumped after a report indicating that Seagen was in talks with multiple suitors about a potential sale of itself.”

test, cancer, researcher, research, dna, bio, clean, modern, chemistry, human, white, medical, sample, pipette, life, culture, laboratory, biotechnology, genetic, disease,

science photo/Shutterstock.com

Seagen Inc. (NASDAQ:SGEN) is not on the list of 30 Most Popular Stocks Among Hedge Funds. Seagen Inc. (NASDAQ:SGEN) was held by 54 hedge fund portfolios at the end of the second quarter compared to 49 in the previous quarter.

We discussed Seagen Inc. (NASDAQ:SGEN) in another article and shared the best stocks to buy according to billionaire Steve Cohen. You can check out our hedge fund investor letters Q2 2022 page for more investor letters from hedge funds and other prominent investors.

Disclosure: None. This article is originally published at Insider Monkey.